Evaluating the Expression Levels of MicroRNA-10b in Patients with Gliomas
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes.
Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas,
known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b
(mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue.
This study tests the hypothesis that in primary glioma samples mir-10b expression patterns
will serve as a prognostic and diagnostic marker. This study will also characterize the
phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the
critical function of anti-mir-10b in blocking established glioblastoma growth, the
investigators will test in vitro the sensitivity of individual primary tumors to
anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from
patients diagnosed with gliomas over a period of two years. These samples will be examined
for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic
variations will be correlated to mir-10b expression levels.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.